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tions. Seven state Markov model (chronic HCV, sustained virological response,
compensated cirrhosis, hepatocellulare carcinoma, liver transplantation and
death) was used to estimate clinical effects and costs in lifetime horizon, from
Polish public payer perspective. Direct medical costs were considered. Separate
analysis was done for genotypes 1,4 (48-week treatment) and genotypes 2,3 (24-
week treatment). Clinical practice and cost data were gathered from clinical ex-
perts or based on the National Health Fund and Ministry of Health published price
lists. Sensitivity analysis was conducted in order to assess the robustness of the
results. RESULTS: Genotypes 1 and 4: total costs were 92 036 PLN (1 Euro3.96 PLN)
for PegIFN2a and 87 793 PLN for PegIFN2b. Average survival of HCV patient
treated with PegIFN2a was 27.9 life years (LY) and 14.83 quality adjusted life years
(QALY) and treated with PegIFN2b was 27.63 LYs and 14.61 QALYs. The incremen-
tal cost-effectiveness ratio was 15 878 PLN/LYG and incremental cost-utility ratio
was 19 763 PLN/QALY. Values of both ratios fall below the cost-effectiveness
threshold assumed in Poland (100 000 PLN/LYG or QALY). Genotypes 2 and 3: Total
costs were 32 849 PLN for PegIFN2a and 38 071 PLN for PegIFN2b. Average survival
of HCV patient treated with PegIFN2a was 30.79 LYs and 17.15 QALYs and treated
with PegIFN2b was 30.20 LYs and 16.68 QALYs. The PegIFN2a dominated
PegIFN2b. The results were confirmed in sensitivity analysis. CONCLUSIONS:
PegIFN2a is a clinically effective and safe treatment for HCV patients and is highly
cost-effective (or dominant) from Polish public payer perspective.
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OBJECTIVES: Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-
valent pneumococcal conjugate vaccine (PCV10) are two approved vaccines for the
active immunization against Streptococcus pneumoniae, causing invasive pneumo-
coccal disease in infants and children. PCV13 offers broader protection against
Streptococcus pneumoniae; however, PCV10 offers potential additional protection
against non-typeable Haemophilus influenzae. We examined public health and eco-
nomic impacts of a PCV10 and PCV13 pediatric national immunization programs
(NIPs) in Canada.METHODS: A decision-analytic model was developed to examine
the costs and outcomes associated with a 21 dosing of PCV10 and 21 dosing of
PCV13 pediatric NIP. The model followed patients over the remainder of their life-
time. Recent disease incidence, serotype coverage, population data, percent vacci-
nated, costs, and utilities were obtained from the published literature. Direct and
indirect effects were derived from 7-valent pneumococcal vaccine. Additional di-
rect effect of 4% was attributed to PCV10 for moderate to severe AOM to account for
potential non-typeable Haemophilus influenzae benefit. Annual number of disease
cases and costs (2010 CAN$) were presented. RESULTS: In Canada, PCV13 pre-
vented more cases of disease (7,465 when considering direct effects only and 49,340
when considering both direct and indirect effects) than PCV10. This translated to
population gains of 80,565 to 94,134 more quality-adjusted life years when vacci-
nating with PCV13 versus PCV10. Use of PCV13 in children also reduced annual
direct medical costs (including the cost of vaccination) by $5.8 to $132.8 million.
Thus, PCV13 was found to dominate PCV10. One-way sensitivity analyses showed
PCV13 to always be dominant or cost-effective versus PCV10. CONCLUSIONS: Con-
sidering the epidemiology of pneumococcal disease in Canada, 21 dosing of
PCV13 is shown to be a cost saving immunization program as it provides substan-
tial public health and economic benefits relative to 21 dosing of PCV10.
PIN55
COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN
HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
Jakubczyk M1, Pawe˛ska J2, Niewada M2, Berak H3, Szkultecka-De˛bek M4,
Russel-Szymczyk M4
1Warsaw School of Economics, Warsaw, Poland, 2HealthQuest spoˇłka z ograniczona˛
odpowiedzialnos´cia˛ Sp. K., Warsaw, Poland, 3Hospital for Infection Disease, Warsaw, Poland,
4Roche Polska Sp. z o.o., Warsaw, Poland
OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-positive chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (HBeAg se-
roconversion), relapse, complications (compensated/decompensated cirrhosis,
hepatocellular carcinoma, liver transplantation) and death. Quality-adjusted life
years (QALYs) were the measure of effectiveness. Short-term efficacy assessment
was based on the results of randomized clinical trials (RCTs). Long-term efficacy
data for nucleos(t)ide analogues (NAs) were derived from published models and
RCTs extensions. Utilities and transition probabilities (spontaneous response, re-
lapse, complications, death) were taken from published literature. Direct medical
costs, i.e. costs of drugs and procedures used in the treatment of CHB and its
complications were obtained using a survey conducted among Polish clinicians. In
the base case analysis costs and benefits were discounted at a 5% and 3.5% annual
rate, respectively. The robustness of the results was assessed using one-way, sce-
nario and probabilistic sensitivity analyses. RESULTS: In both the short and long-
term analysis PegIFN-2a increased number of QALYs and life years gained (LYGs)
compared to all investigated NAs. In the short-term model PegIFN-2a decreased
the costs of complications’ treatment and increased the overall costs due to drug
acquisition cost. ICER for PegIFN-2a vs. lamivudine, adefovir and entecavir
amounted to 50,809, 11,442 and 39,588 PLN/QALY, respectively (1€4 PLN). In the
long-term model costs of NAs were higher. PegIFN-2a was cost-saving and dom-
inated adefovir and entecavir, while ICER versus lamivudine amounted to 27,431
PLN/QALY. Sensitivity analysis proved these results to be robust. CONCLUSIONS:
Peginterferon alfa-2a is cost-effective when compared to adefovir, entecavir and
lamivudine in Poland.
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OBJECTIVES: IMPACT trial showed that prolonged prophylaxis of 200 days with
valganciclovir (VGC 200) compared with 100 days (VGC 100) significantly decreases
the incidence of cytomegalovirus (CMV) disease. Therefore, a cost-effectiveness
model was developed to evaluate prolonged prophylaxis of 200 days with valgan-
ciclovir and its long term economic impact . METHODS: A Markov model was
designed to simulate the CMV disease progression; costs and outcomes associated
with the use of VGC 200 vs VGC 100 in a cohort of 10,000 patients over 10 years was
examined. Data of the disease evolution were obtained from the IMPACT (Humar,
Am J Transplant 2010) for year 1 and the available scientific evidence for years 2-10.
The analysis was conducted from the perspective of the Spanish National Health-
care System (SNHS), considering direct medical costs. Unitary costs (€, 2010) were
obtained from a Spanish database. Utility values were obtained from literature. The
annual discount rate was 3% for costs and outcomes. RESULTS: Treatment with
VGC 200 provides better results in health than VGC 100 (50,020.30 vs. 47,639.90
QALY/patient). The average overall cost per patient is €1,121,327 with VGC 200 and
€1,131,187 with VGC 100. The savings per patient treated with VGC 200 in 10 years
is €986. Sensitivity analysis confirms the stability of the results. CONCLUSIONS:
Treatment of patients with prolonged prophylaxis valganciclovir reduces the inci-
dence in high risk kidney transplant recipients and is a cost-saving strategy in CMV
disease management from the perspective of the SNHS.
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OBJECTIVES: In Uganda, 91,000 children are born annually to HIV-positive moth-
ers, approximately 25,000 of which become HIV-infected. New guidelines recom-
mend the use of combination antiretroviral therapy (cART) to prevent vertical
transmission. We evaluate the cost-effectiveness of more costly cART relative to
other or no preventative therapies. METHODS: Currently, about 48.4% of HIV-pos-
itive pregnant women do not receive any preventive therapies and therefore have
a 40% risk of transmitting HIV to their child during pregnancy or breastfeeding.
This risk can be reduced to 25.8% by single dose nevirapine (sdNVP; Cost: US$0.06),
to 17.4% by dual therapy (3TC/AZT; Cost: US$16 for 7 weeks) and to 3.8% by cART
(Cost: US$470 for 18 months). At CD4 counts below 350 cells/l, lifetime cART is
indicated for the mother (Cost: US$ 6,883), which reduces future transmission risk
in an additional 3.49 pregnancies. The model calculates disability adjusted life
years (DALY’s) between therapies based on differences in HIV-transmission to chil-
dren, which results in shortened life-expectancy. All costs and benefits are dis-
counted at 3% annually. RESULTS: Replacing sdNVP and 3TC/AZT with cART could
reduce annual HIV transmissions by 7,500 cases. Preventing one infection averts
23.7 DALY’s. Hence, DALY’s averted using 18 months cART versus sdNVP, 3TC/AZT,
and no therapies are 5.21, 3.22, and 8.58, and yield a cost/DALY averted of US$46,
US$99, and US$34, respectively. The corresponding figures for lifetime cART are
19.20, 11.87, and 31.60, resulting in a cost/DALY averted of US$205, US$354 and
US$172, respectively. CONCLUSIONS: Using the 1 time per capita GDP threshold
(US$460), cART as proposed in the new Ugandan guidelines is highly cost-effective
relative to other drugs and would generate additional value if treatment could
reach greater numbers of women. It remains highly cost-effective even if treatment
is continued over the patients’ lifetimes. It is imperative that these guidelines are
rapidly implemented.
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OBJECTIVES: It is estimated that pneumococcal disease is responsible for more
than a million deaths per year in children less than five years of age worldwide.
This study aim to perform a cost-effectiveness analysis comparing pneumococcal
13-valent conjugate vaccine (PCV13) against pneumococcal 10-valent conjugate
vaccine in prevention of invasive pneumococcal diseases (IPD), acute otitis media
(AOM) and pneumonia, from the São Paulo Public Healthcare System perspective.
METHODS: The type of study was cost-effectiveness analysis based on a decision
tree model to estimate costs and consequences of prophylaxis. Epidemiological
and efficacy data was collected from a critical appraisal of the scientific literature,
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